Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease is characterized by amyloid-beta plaques, neurofibrillary tangles, gliosis, and neuronal loss. Solanezumab, a humanized monoclonal antibody, preferentially binds soluble forms of amyloid and in preclinical studies promoted its clearance from the brain. METHODS: In two phase 3, double-blind trials (EXPEDITION 1 and EXPEDITION 2), we randomly assigned 1012 and 1040 patients, respectively, with mild-to-moderate Alzheimer's disease to receive placebo or solanezumab (administered intravenously at a dose of 400 mg) every 4 weeks for 18 months. The primary outcomes were the changes from baseline to week 80 in scores on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog11; range, 0 to 70, with higher scores indicating greater cognitive impairment) and the Alzheimer's Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL; range, 0 to 78, with lower scores indicating worse functioning). After analysis of data from EXPEDITION 1, the primary outcome for EXPEDITION 2 was revised to the change in scores on the 14-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog14; range, 0 to 90, with higher scores indicating greater impairment), in patients with mild Alzheimer's disease. RESULTS: Neither study showed significant improvement in the primary outcomes. The modeled difference between groups (solanezumab group minus placebo group) in the change from baseline was -0.8 points for the ADAS-cog11 score (95% confidence interval [CI], -2.1 to 0.5; P=0.24) and -0.4 points for the ADCS-ADL score (95% CI, -2.3 to 1.4; P=0.64) in EXPEDITION 1 and -1.3 points (95% CI, -2.5 to 0.3; P=0.06) and 1.6 points (95% CI, -0.2 to 3.3; P=0.08), respectively, in EXPEDITION 2. Between-group differences in the changes in the ADAS-cog14 score were -1.7 points in patients with mild Alzheimer's disease (95% CI, -3.5 to 0.1; P=0.06) and -1.5 in patients with moderate Alzheimer's disease (95% CI, -4.1 to 1.1; P=0.26). In the combined safety data set, the incidence of amyloid-related imaging abnormalities with edema or hemorrhage was 0.9% with solanezumab and 0.4% with placebo for edema (P=0.27) and 4.9% and 5.6%, respectively, for hemorrhage (P=0.49). CONCLUSIONS: Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability. (Funded by Eli Lilly; EXPEDITION 1 and 2 ClinicalTrials.gov numbers, NCT00905372 and NCT00904683.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Florbetapir PET analysis did not show a reduction in brain amyloid deposits with solanezumab [45, 46].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [45]
In the citing paper
“bapineuzumab and solanezumab showed no cognitive improvement in Phase 3 trials [46,47]”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [46]
In the citing paper
“Clinical trials often fail to deliver benefits.”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [46]
In the citing paper
“and a similar proportion has normal amyloid PET or CSF Aβ42 studies [53–62].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [57]
In the citing paper
“While recent clinical trials of anti‐amyloid therapies, such as donanemab and lecanemab, 2 , 3 have shown promising results, the failures of earlier treatments like solanezumab and bapineuzumab indicate that targeting a single AD‐specific pathological process is insufficient to mitigate cognitive decline. 4 , 5 , 6”
From White matter hyperintensity modulates the amyloid‐tau‐cognition association and anti‐amyloid treatment efficacy in asymptomatic older adults (2025) · cites this paper as [6]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Sheikh (1986) · doi:10.1300/j018v05n01_09 · Cited by 7,236
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Assessing Quality of Life in Older Adults With Cognitive Impairment
Logsdon, R. G., Gibbons, L. E., McCurry, S. M., & Teri, L. (2002) · Psychosomatic Medicine · doi:10.1097/00006842-200205000-00016 · Cited by 1,381
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Self-citationAn Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease
Galasko, D., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00005 · Cited by 1,194
Self-citationO’Bryant, S. E. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1091 · Cited by 884
Research works printed but not linked: 2
- Wimo A, Wetterholm AL, Mastey V, Winbald B. Evaluations of resource utilization and caregiver time in anti-dementia drug trials- a quantitative battery. In: Wimo A, Jonsson B, Karlsson G, Winbald B, eds. The health economics of dementia. London: John Wiley, 1998:465-99.
- Kind P. 1996. The EuroQol instrument: an index of health-related quality of life. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996:191-201.
Cited by
Items 901–1,000 of 1,006
Role of Pharmacogenomics in Individualizing Treatment for Alzheimer’s Disease
Argueta, N., Notari, E., & Szigeti, K. (2022) · CNS Drugs · doi:10.1007/s40263-022-00915-3 · Cited by 19
“In two phase III studies of solanezumab, EXPEDITION 1 and EXPEDITION 2, no benefit was seen in regard to the co-primary endpoints, but a post hoc analysis suggested benefit in the early APOE4 carrier group [8].”
BackgroundTRPC Channels and Alzheimer’s Disease
Lu, R., Qian, H., & Wang, J. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-94-024-1088-4_7 · Cited by 18
Gao, C., Wu, Q. J., Sun, J.-X., Song, X., Wang, J., Xiong, C., & Teng, F. (2017) · Neural Regeneration Research · doi:10.4103/1673-5374.215261 · Cited by 18
“Alzheimer’s disease (AD) is a common form of dementia that typically occurs during old age (Schott et al., 2006; Doody et al., 2014; Dubois et al., 2014; Nelson et al., 2014; Aron and Yankner, 2016; Canter et al., 2016; Reiman, 2016; Roy et al., 2016; Shrestha and Klann, 2016; Tycko, 2016).”
BackgroundFeldman, H. H., & Estabrooks, C. A. (2017) · Canadian Journal of Public Health · doi:10.17269/cjph.108.5852 · Cited by 17
The Role of Amyloid- and Tau PET in the New Era of Alzheimer Disease Therapies
Chiotis, K., Wang, Y., Joie, R. L., & Rabinovici, G. D. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268339 · Cited by 26
Bayer, T. A. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.710579 · Cited by 20
You, M., Wang, K., Pan, Y., Tao, L., Ma, Q., Zhang, G., & Hu, F. (2022) · Food & Function · doi:10.1039/d1fo02397g · Cited by 20
Experimental approaches for altering the expression of Abeta‐degrading enzymes
Loeffler, D. A. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15762 · Cited by 20
“A small but statistically significant slowing of cognitive impairment was found with Solanezumab for patients with mild AD (Doody et al., 2014), although its effectiveness in this population was subsequently questioned (Doggrell, 2018).”
BackgroundCohen, D. E., Kim, H., Levine, A., Devanand, D. P., Lee, S., & Goldberg, T. E. (2023) · International Psychogeriatrics · doi:10.1017/s1041610223000911 · Cited by 23
“For instance, pharmaceutical trials have shown limited ability to improve cognitive outcomes in patients with Alzheimer ’ s disease (Alexander et al ., 2021; Doody et al ., 2014).”
Intravenous immunoglobulin for Alzheimer's disease
Relkin, N. R. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12500 · Cited by 18
Kwon, H., Crisostomo, A. C., Smalls, H. M., & Finke, J. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120420 · Cited by 17
The need for thorough phase II studies in medicines development for Alzheimer’s disease
Gray, J. A., Fleet, D., & Winblad, B. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0153-y · Cited by 17
Action of anti-TNF-α drugs on the progression of Alzheimer's disease: A case report
Camargo, C. H. F., Justus, F. F., Retzlaff, G., Blood, M. R. Y., & Schafranski, M. D. (2015) · Dementia & Neuropsychologia · doi:10.1590/1980-57642015dn92000015 · Cited by 20
Emerging links between cell competition and Alzheimer's disease
Coelho, D. S., & Moreno, E. (2019) · Journal of Cell Science · doi:10.1242/jcs.231258 · Cited by 22
“However, results so far have been discouraging, as new drugs failed to significantly improve cognitive functions in clinical trials, in spite of occasional observations of decreased Aβ load (Doody et al., 2014; Holmes et al., 2008; Salloway et al., 2014).”
ResultNanomedicines for Subcellular Targeting: The Mitochondrial Perspective
Oladimeji, O., Akinyelu, J., & Singh, M. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666191125092111 · Cited by 17
Kang, M. S., Shin, M., Ottoy, J., Aliaga, A., Mathotaarachchi, S. S., Quispialaya, K. M., Pascoal, T. A., Collins, D. L., Chakravarty, M. M., Mathieu, A. P., et al. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x211035625 · Cited by 19
From mice to mind: Strategies and progress in translating neuroregeneration
Burns, T. C., & Verfaillie, C. M. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.041 · Cited by 18
A New Use for an Old Treatment: Radiation Therapy and Alzheimer's Disease
Wilson, G. D., & Marples, B. (2016) · Radiation Research · doi:10.1667/rr14367.1 · Cited by 18
Potential Use of Nanomedicine for the Anti-inflammatory Treatment of Neurodegenerative Diseases
Otero, M. D. C., Espinosa‐Oliva, A. M., Herrera, A. J., García-Domínguez, I., Arévalo, M. F., Martín‐Banderas, L., & de Pablos, R. M. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612824666180403113015 · Cited by 20
Chundu, U. C., Thiriveedhi, S. R., Bhatti, C., Mupparaju, J. S., Otinashvili, N., & Gelishvili, E. (2025) · Cureus · doi:10.7759/cureus.85377 · Cited by 17
Hao, L., Jia, J., Xing, Y., & Han, Y. (2022) · Brain and Behavior · doi:10.1002/brb3.2709 · Cited by 20
A review of therapeutic failures in late-stage clinical trials
Jain, R., Subramanian, J., & Rathore, A. S. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2161366 · Cited by 25
Dang, M., Yang, C., Chen, K., Lu, P., Li, H., Zhang, Z., & for the Beijing Aging Brain Rejuvenation Initiative, F. T. A. D. N. I. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01167-z · Cited by 16
“With the many clinical treatment failures for Alzheimer’s disease (AD) [3, 4], MCI has gradually become regarded as a critical time window for disease treatment and intervention [5–8].”
BackgroundMonoclonal antibody therapy for Alzheimer's disease focusing on intracerebral targets
Gu, X., Long, Q., Qi, Q., Zhou, J., Chen, S., & Wang, L. (2024) · BioScience Trends · doi:10.5582/bst.2023.01288 · Cited by 19
Development of disease‐modifying therapies against Alzheimer's disease
Iwatsubo, T. (2024) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13681 · Cited by 20
Self-citationEngineered Antibodies to Improve Efficacy against Neurodegenerative Disorders
Niazi, S., Mariam, Z., & Magoola, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126683 · Cited by 13
“…considering A β aggregates as antigens [151], A β aggregation inhibition [152], β -secretase inhibition [153], γ -secretase modulation [154], γ -secretase inhibition [155], intravenous immunoglobulin (IVIG) administration [156], and most widely introducing monoclonal anti-A β antibodies [157].”
BackgroundAmyloid-β Clearance with Monoclonal Antibodies: Transforming Alzheimer’s Treatment
Fatima, R., Khan, Y., Maqbool, M., Ramalingam, P. S., Khan, M. G., Bisht, A. S., & Hussain, M. S. (2025) · Current Protein and Peptide Science · doi:10.2174/0113892037362037250205143911 · Cited by 20
Evolving Relevance of Neuroproteomics in Alzheimer’s Disease
Lista, S., Zetterberg, H., O’Bryant, S. E., Blennow, K., & Hampel, H. J. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6952-4_5 · Cited by 16
Wu, X., Kosaraju, J., Zhou, W., & Tam, K. Y. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.003 · Cited by 16
“To our disappointment, recent studies report that Ab immunotherapy accelerates the clearance of Ab oligomers and fibrils, rather than ameliorating the memory impairment and cognitive deficits (Doody et al., 2014; Farlow et al., 2015; Paquet et al., 2015; Salloway et al., 2011).”
BackgroundThe Neuroprotection of KIBRA in Promoting Neuron Survival and Against Amyloid β-Induced Apoptosis
Song, L., Tang, S. H., Dong, L., Han, X., Cong, L., Dong, J., Han, X., Zhang, Q., Wang, Y., & Du, Y. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00137 · Cited by 17
Immunotherapy Targeting Amyloid-ß Peptides in Alzheimer’s Disease
Zampar, S., & Wirths, O. (2020) · Exon Publications eBooks · doi:10.36255/exonpublications.alzheimersdisease.2020.ch2 · Cited by 27
“However, both showed a lack of efficacy with regard to cognitive performance, the primary outcome measure of both studies (105).”
BackgroundThe Development of Pharmacological Therapies for Alzheimer’s Disease
Ping, L., Sun, J., Cheng, Q., Yang, Y., Cordato, D. J., & Gao, J. (2021) · Neurology and Therapy · doi:10.1007/s40120-021-00282-z · Cited by 17
“In the first two phase III trials (EXPEDITION and EXPEDITION2), solanezumab was tested in mild-tomoderate AD patients, with no significant reductions found in cognitive or functional decline [22].”
BackgroundWinston, C. N., Langford, O., Levin, N., Raman, R., Yarasheski, K. E., West, T., Abdel‐Latif, S., Donohue, M., Nakamura, A., Toba, K., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221118 · Cited by 19
Self-citationImpact of amyloid β aggregate maturation on antibody treatment in APP23 mice
Balakrishnan, K., Upadhaya, A. R., Steinmetz, J. L., Reichwald, J., Abramowski, D., Fändrich, M., Kumar, S., Yamaguchi, H., Walter, J., Staufenbiel, M., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0217-z · Cited by 16
Alzheimer's disease clinical trials: past failures and future opportunities
Yaari, R., & Hake, A. M. (2015) · Clinical Investigation · doi:10.4155/cli.14.127 · Cited by 17
Powell, T. P. (2018) · Current Psychiatry Reports · doi:10.1007/s11920-018-0868-0 · Cited by 19
Brain-targeted intranasal delivery of biologics: a perspective for Alzheimer's disease treatment
Li, H., Shen, X., Zhang, B., Li, Y., Alexander, C., Harvey, P., & Zhu, Z. (2025) · RSC Pharmaceutics · doi:10.1039/d5pm00148j · Cited by 22
Inamdar, A., Bugadannavar, P., Palled, M. S., Umarani, S., Salve, P. S., Gurupadayya, B., Patil, P. D., & Sharma, H. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1614962 · Cited by 23
Feng, L., Chong, M.-S., Lim, W. S., Lee, T., Kua, E. H., & Ng, T.-P. (2015) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2015.57 · Cited by 16
Gu, L., Cai, N., Li, M., Bi, D., Yao, L., Fang, W., Wu, Y. L., Hu, Z., Liu, Q., Lin, Z., et al. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.892558 · Cited by 16
“Owing to the elusive pathogenesis of AD, the single-target anti-AD drugs appear to be unsuccessful based on failed clinical trials (13, 14).”
BackgroundLyu, D., Lyu, X., Huang, L. T., & Fang, B. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101959 · Cited by 15
Kim, J., Jeon, H., Kim, H. Y., & Kim, Y. S. (2023) · ChemBioChem · doi:10.1002/cbic.202300328 · Cited by 17
Ashwini, P., Bodhankar, S. L., Muthal, A., Kumar, D., Pawar, A., & Kulkarni, R. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.11.016 · Cited by 19
“A study of 1000 mild to moderate AD patients who were administered intravenously 400 mg Solanezumab every four weeks for 80 weeks failed to show its efficacy 67 .”
Perspectives for treating Alzheimer's disease: a review on promising pharmacological substances
Cazarim, M. D. S., Moriguti, J. C., Ogunjimi, A. T., & Pereira, L. R. L. (2016) · Sao Paulo Medical Journal · doi:10.1590/1516-3180.2015.01980112 · Cited by 19
Wang, S.-W., Liu, D., Zhang, L. L., Ji, M., Zhang, Y., Dong, Q.-X., Liu, S., Xie, X.-X., & Liu, R. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0267-5 · Cited by 16
“Passive immunotherapy using antibodies against Aβ monomers, such as bapineuzumab [19] and solanezumab [20], was also unsuccessful in AD clinical trials.”
BackgroundXing, H., Li, B., Peng, D., Wang, C., Wang, G., Li, P., Le, Y., Wang, J., Ye, G., & Chen, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180076 · Cited by 15
Cuddy, L. K., Seah, C., Pasternak, S., & Rylett, R. J. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00361 · Cited by 17
“Solanezumab, a mid-region-directed Aβ antibody recognizing residues 13–28 of Aβ showed a significant 33% reduction in rate of decline in patients withmild AD (Doody et al., 2014).”
BackgroundMolecular imaging: What is right and what is an illusion?
Klunk, W. E. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.01.004 · Cited by 15
“[15] Doody RS, Thomas RG, FarlowM, Iwatsubo T, Vellas B, Joffe S, et al.”
Quantitative multimodal multiparametric imaging in Alzheimer’s disease
Zhao, Q., Chen, X., & Zhou, Y. (2016) · Brain Informatics · doi:10.1007/s40708-015-0028-9 · Cited by 17
The development of biological therapies for neurological diseases: moving on from previous failures
Qosa, H., & Volpe, D. A. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1437142 · Cited by 15
“Thus, presumably due to its low central exposure in humans, solanezumab failed to improve cognition or functional ability of mild-to-moderate AD patients in two phase-III clinical trials [18].”
BackgroundPlant-based vaccines for Alzheimer’s disease
Ishiura, S., & Yoshida, T. (2019) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.95.020 · Cited by 15
Safety and Efficacy of Donepezil 10 mg/day in Patients with Mild to Moderate Alzheimer’s Disease
Jia, J., Wei, C., Chen, W., Jia, L., Zhou, A., Wang, F., Tang, Y., & Xu, L. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190940 · Cited by 15
García‐Alberca, J. M., Mendoza, S., Gris, E., Royo, J. L., Cruz-Gamero, J. M., & García‐Casares, N. (2020) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5366 · Cited by 14
“Currently, there is no cure for AD and several large clinical trials using experimental disease modifying therapies for established AD have failed.(2,3) Furthermore, drugs are being administered too late by the time substantial and irreversible synaptic and neuronal loss has already occurred in critical brain regions.”
BackgroundForlenza, O. V., & Barbosa, B. J. A. P. (2025) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2025-e001 · Cited by 22
Anti-amyloid monoclonal antibody therapies in Alzheimer’s disease – a scoping review
Elamin, S. A., Shibli, A. N. A., Shaito, A. A., Al-Maadhadi, M., Zolezzi, M., & Pedersen, S. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.10.011 · Cited by 19
Predicting conversion of brain β-amyloid positivity in amyloid-negative individuals
Park, C. J., Seo, Y., Choe, Y. S., Jang, H., Lee, H., Kim, J. P., & Initiative, A. D. N. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01067-8 · Cited by 15
Dickson, S. P., Hennessey, S., Johnson, J. N., Knowlton, N., & Hendrix, S. B. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01238-1 · Cited by 16
“within the range seen in contemporary clinical trials in this patient population [26, 27], albeit less than the change assumed in study planning.”
BackgroundRecent Trends in Active and Passive Immunotherapies of Alzheimer’s Disease
Alshamrani, M. (2023) · Antibodies · doi:10.3390/antib12020041 · Cited by 22
“This indicated good safety trials, but cognitive function was not improved [148].”
BackgroundSignal Pathways and Intestinal Flora through Trimethylamine N-oxide in Alzheimer's Disease
Zhang, Y., & Jian, W. (2023) · Current Protein and Peptide Science · doi:10.2174/1389203724666230717125406 · Cited by 14
Updates on pharmacological treatment for Alzheimer’s disease
Tipton, P. W. (2024) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.96286 · Cited by 17
A case for seeking sex-specific treatments in Alzheimer’s disease
Lynch, M. A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1346621 · Cited by 20
Alzheimer’s disease and immunotherapy
Qin, W., Pang, Y., Nie, S., Quan, M., & Jia, J. (2024) · Current Medicine · doi:10.1007/s44194-024-00035-8 · Cited by 16
“In patients with mild to moderate AD, solanezumab failed to significantly slow the rate of cognitive decline and brain atrophy (Doody et al. 2014; Honig, Vellas et al., 2018).”
Passive Anti-amyloid Beta Monoclonal Antibodies: Lessons Learned over Past 20 Years
Wicker, A., Shriram, J., Decourt, B., & Sabbagh, M. N. (2024) · Neurology and Therapy · doi:10.1007/s40120-024-00664-z · Cited by 18
“Interestingly, an additional subgroup analysis did indicate that patients with mild AD showed a 34% decrease in cognitive decline, which was statistically significant [21].”
ResultJeremic, D., Navarro‐López, J. D., & Jiménez‐Díaz, L. (2025) · Journal of Medical Internet Research · doi:10.2196/68454 · Cited by 20
Amyloid in dementia associated with familial FTLD: not an innocent bystander
Naasan, G., Rabinovici, G. D., Ghosh, P. M., Elofson, J., Miller, B. L., Coppola, G., Karydas, A., Fong, J. C., Perry, D. C., Lee, S. E., et al. (2015) · Neurocase · doi:10.1080/13554794.2015.1046458 · Cited by 15
Lyketsos, C. G., Holroyd, K., Fosdick, L., Smith, G. S., Leoutsakos, J., Munro, C. A., Oh, E. S., Drake, K. E., Rosenberg, P., Anderson, W. S., et al. (2015) · Open Access Journal of Clinical Trials · doi:10.2147/oajct.s81542 · Cited by 16
Cerebrovascular and mitochondrial abnormalities in Alzheimer’s disease: a brief overview
Carvalho, C., Correia, S. C., Perry, G. L., Castellani, R. J., & Moreira, P. I. (2015) · Journal of Neural Transmission · doi:10.1007/s00702-015-1367-7 · Cited by 15
Samra, G. K., Dang, K., Ho, H., Baranwal, A., & Mukherjee, J. (2018) · Medicinal Chemistry Research · doi:10.1007/s00044-018-2178-9 · Cited by 14
“Table 1; Doody et al. 2014; Siemers et al. 2016).”
Lee, W. J., Ham, S. A., Lee, G. H., Choi, M., Yoo, H., Paek, K. S., Lim, D., Hong, K., Hwang, J. S., & Seo, H. G. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14715 · Cited by 15
Chau, D. D., Yung, K. W. Y., Chan, W. W., An, Y., Yan, H., Chan, H. Y. E., Ngo, J. C. K., & Lau, K. (2019) · The FASEB Journal · doi:10.1096/fj.201802825rr · Cited by 13
Cohort profile: the Diet and Healthy Aging (DaHA) study in Singapore
Yu, R., Sun, Y., Ye, K. X., Feng, Q., Lim, S. L., Mahendran, R., Cheah, I. K.-M., Foo, R., Chua, R. Y., Gwee, X., et al. (2020) · Aging · doi:10.18632/aging.104051 · Cited by 17
Nakamura, R., Konishi, M., Higashi, Y., Saito, M., & Akizawa, T. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01229-2 · Cited by 16
“A few Aβ antibodies and vaccines aimed at inhibiting Aβ aggregation are still under development [4, 35, 36].”
BackgroundSchuck, F., Schmitt, U., Reinhardt, S., Freese, C., Lee, I., Thines, E., Efferth, T., & Endres, K. (2015) · Phytomedicine · doi:10.1016/j.phymed.2015.08.001 · Cited by 14
Update on Alzheimer’s and the Dementias
Ringman, J. M. (2017) · Neurologic Clinics · doi:10.1016/j.ncl.2017.01.009 · Cited by 18
Chen, Y., Ni, X., Fleisher, A., Zhou, W., Aisen, P. S. S., & Mohs, R. C. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.12.002 · Cited by 14
Self-citationReduction of Amyloid in the Brain and Retina After Treatment With IVIG for Mild Cognitive Impairment
Kile, S. J., Au, W. J., Parise, C. A., Sohi, J., Yarbrough, T. L., Czeszynski, A., Johnson, K., Redline, D., Donnel, T., Hankins, A. I., et al. (2020) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317519899800 · Cited by 15
Vascular Considerations for Amyloid Immunotherapy
Foley, K. E., & Wilcock, D. M. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01235-1 · Cited by 17
Hao, Y., Dong, M., Sun, Y., Duan, X., & Niu, W. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1147757 · Cited by 13
Fatima, K., Ashfaq, U. A., Qamar, M. T. U., Asif, M., Haque, A., Qasim, M., Alamri, M. A., Muhseen, Z. T., Noor, F., & Sadaqat, M. (2024) · South African Journal of Botany · doi:10.1016/j.sajb.2024.01.001 · Cited by 13
Emerging paradigms in Alzheimer's therapy
Agnes Preethy, H., Rajendran, K., Sukumar, A. J., & Krishnan, U. M. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176872 · Cited by 18
Immunotherapy in Alzheimer’s Disease: Current Status and Future Directions
Vashisth, K., Sharma, S., Ghosh, S., Babu, M. A., Ghosh, S., Iqbal, D., Kamal, M., Almutary, A. G., Jha, S. K., Ojha, S. K., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230603 · Cited by 18
PET/CT/MRI in Clinical Trials of Alzheimer’s Disease
Høilund‐Carlsen, P. F., Alavi, A. A., & Barrio, J. R. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240206 · Cited by 13
Féger, J., & Hirsch, É. C. (2014) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2014.10.001 · Cited by 15
Wu, M., Jia, J., Lei, C., Ji, L., Chen, X., Sang, H., & Xiong, L. (2014) · Journal of Molecular Neuroscience · doi:10.1007/s12031-014-0422-4 · Cited by 14
Shen, J. H. Q., Shen, Q., Yu, H., Lai, J. S., Beaumont, J. L., Zhang, Z., Wang, H., Kim, S. Y., Chen, C., Kwok, T. C. Y., et al. (2014) · Europe PMC (PubMed Central) · Cited by 16
Hendrix, S. B., Ellison, N., Stanworth, S. H., Tierney, L. K., Mattner, F., Schmidt, W., Dubois, B., & Schneeberger, A. (2015) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2015.67 · Cited by 18
Quantile regression to characterize solanezumab effects in Alzheimer's disease trials
Chen, Y., Ma, X., Sundell, K. L., Alaka, K., Schuh, K. J., Raskin, J., & Dean, R. A. (2016) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.07.005 · Cited by 14
Wu, X., Kosaraju, J., & Tam, K. Y. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.03.037 · Cited by 13
“However, the success rate is very low (Doody et al., 2014; Salloway et al., 2014; Schneider et al., 2014).”
BackgroundValls-Comamala, V., Guivernau, B., Bonet, J., Puig, M., Perálvarez‐Marín, A., Palomer, E., Fernàndez‐Busquets, X., Altafaj, X., Tajes, M., Puig‐Pijoan, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17074 · Cited by 16
“Although none of them has overcome phase III for mild to moderate AD until now [30, 31], some trials are still ongoing because of their potential [32, 34, 35].”
BackgroundInfluentialLilamand, M., Cesari, M., Cantet, C., Payoux, P., Andrieu, S., Vellas, B. J., & and the MAPT/DSA study group (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15497 · Cited by 14
Self-citationEpigenetic landscape and AAV targeting of human neocortical cell classes
Mich, J. K., & Gradinaru, V. (2019) · CaltechAUTHORS (California Institute of Technology) · Cited by 15
Zhao, L., Teng, J., Mai, W., Su, J., Yu, B., Nong, X., Li, C., Wei, Y., Duan, G., Deng, X., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.617611 · Cited by 13
“In terms of drug treatment, the recent drugs for tau pathology and β-amyloid (Aβ) fail to treat the disease in the stage of mild or moderate dementia (Doody et al., 2014; Salloway et al., 2014).”
BackgroundNovel bioengineered MBenes for the treatment of Alzheimer's disease: An in-Sillico study
Dahri, M., Jahromi, A. M., Nikzad, A., Mohammadgholian, M., Rahmanian, M., Abolmaali, S. S., & Maleki, R. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1969288 · Cited by 13
“These intensive studies resulted in the development of various drugs such as Bapineuzumab (Salloway et al., 2014), Solanezuma (Doody et al., 2014), Gantenerumab (Ostrowitzki et al., 2017), Avagacestat, (Coric et al., 2015), Idalopirdine, and Verubecestat (Atri et al., 2018; Egan et al., 2018),…”
BackgroundMatheson, A. (2016) · The Hastings Center Report · doi:10.1002/hast.576 · Cited by 14
Chertkow, H. M. (2018) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2018.27 · Cited by 17
“The progress to date in developing effective pharmacological treatment options has been disappointing (30-32), underscoring the need to understand better what contributes to the dementia syndrome in different generational cohorts as well as in different populations (33).”
Preparation and in vitro activity of single chain antibodies against Alzheimer's disease
Fu, L., Zhang, Y., Zhang, X., Tian, W., Zhang, W., Jia, Y. X., & Zhang, L. (2020) · Immunology Letters · doi:10.1016/j.imlet.2020.07.009 · Cited by 13
Targeting mRNA for Alzheimer’s and Related Dementias
Wolfe, M. S. (2014) · Scientifica · doi:10.1155/2014/757549 · Cited by 14
Emerging amyloid disease-modifying drugs for Alzheimer’s disease
Galimberti, D., & Scarpini, E. A. (2016) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2016.1146678 · Cited by 15
Clinical trials in Alzheimer's disease
Delrieu, J., & Vellas, B. J. (2015) · Wiley eBooks · doi:10.1002/9781118323434.ch9 · Cited by 13
Self-citationVellas, B. J. (2021) · The journal of nutrition health & aging · doi:10.1007/s12603-021-1657-8 · Cited by 14
Self-citation
Metadata
- Authors
- Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., & Mohs, R.
- Affiliations
- Baylor College of Medicine (US)
- University of California San Diego (US)
- Indiana University (US)
- The University of Tokyo (JP)
- Centre Hospitalier Universitaire de Toulouse (FR)
- University of Pennsylvania (US)
- University of Rochester Medicine (US)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-01-23
- Volume
- 370
- Issue
- 4
- Pages
- 311-321
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2015484447
- Cited by
- 1,668
- References
- 28
- Citations by year
- 2026: 63 · 2025: 84 · 2024: 110 · 2023: 116 · 2022: 101 · 2021: 103 · 2020: 154 · 2019: 145 · 2018: 155 · 2017: 163 · 2016: 183 · 2015: 178 · 2014: 111
- FWCI
- 140.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- solanezumab, Alzheimer's disease, amyloid-beta, anti-amyloid monoclonal antibodies, cognitive impairment, activities of daily living, mild to moderate Alzheimer's disease, placebo response
- MeSH terms
- Activities of Daily Living, Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Cognition, Double-Blind Method, Female, Humans, Male, Neuropsychological Tests, Severity of Illness Index, Biomarkers, Amyloid beta-Peptides, tau Proteins, Treatment Failure, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.